Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma (Q46568714)

23 December 2017

title

Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma (English)

1 reference

23 December 2017

author name string

Rehan Khan

1

1 reference

23 December 2017

Manoj Sharma

2

1 reference

23 December 2017

Lalit Kumar

3

1 reference

23 December 2017

Syed Akhtar Husain

4

1 reference

23 December 2017

Alpana Sharma

5

1 reference

23 December 2017

publication date

13 September 2012

1 reference

23 December 2017

published in

Annals of Hematology

1 reference

23 December 2017

volume

92

1 reference

23 December 2017

issue

1

1 reference

23 December 2017

page(s)

101-109

1 reference

23 December 2017

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

1 reference

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Bone marrow angiogenesis in patients with active multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Cyclooxygenases in cancer: progress and perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Expression of cyclooxygenase-2 in Hodgkin's lymphoma: its role in cell proliferation and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

COX-2 inhibitors. A new class of antiangiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Scatter-factor and semaphorin receptors: cell signalling for invasive growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

How to make tubes: signaling by the Met receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Angiopoietins in tumours: the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Exploring the genomes of cancer cells: progress and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Thiothalidomides: Novel Isosteric Analogues of Thalidomide with Enhanced TNF-α Inhibitory Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Not just angiogenesis--wider roles for the angiopoietins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Cyclooxygenase isozymes are expressed in human myeloma cells but not involved in anti-proliferative effect of cyclooxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1572-5

10.1007/S00277-012-1572-5

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

22971811

1 reference

23 December 2017